RISK FACTORS FOR CORONARY HEART DISEASE

Coronary heart disease (CHD) remains one of the leading causes of death and disability worldwide, which makes it an urgent topic for study and discussion. The modern view of the problem of coronary heart disease suggests an integrated approach to understanding the risk factors that contribute to the development of this disease. Traditionally, the main risk factors were hypertension, dyslipidemia, smoking, diabetes mellitus, and obesity. However, recent research shows that other aspects should be added to this list: genetic predisposition and stress levels.
An analysis of the studies presented in this review shows that dyslipoproteinemia (ApoV/ApoA1), smoking, psychosocial factors, diabetes mellitus, hypertension, abdominal obesity, alcohol, low physical activity, and insufficient fruit intake are the most significant risk factors for coronary heart disease. Recently, special attention has been paid to psychoemotional/psychosocial factors that require careful consideration in the framework of prevention, treatment and rehabilitation of patients.

1. Møller A.L., Vasan R.S., Levy D., Andersson Ch., Lin H. Integrated omics analysis of coronary artery calcific ations and myocardial infarction: the Framingham Heart Study. Scientific Reports. 2023 Dec 7. 13(1). 21581. doi: 10.1038/s41598-023-48848-1.

2. Aksenova E.I., Korotkova E.O., Gorbatov S.Yu., Kamynina N.N. Monitoring of risk factors for non–communicable diseases of the adult population: international experience. Review. M.: State Budgetary Institution of the city of Moscow "Scientific Research Institute of Health Organization and Medical Management of the Department of Health of the City of Moscow". 2022. ISBN 978-5-907404-93-9. In Russian.

3. Drapkina O.M., Kontsevaya A.V., Kalinina A.M, et al. Prevention of chronic non-communicable diseases in the Russian Federation. National Leadership 2022. Cardiovascular therapy and prevention. 2022. 21(4). 3235. doi: 10.15829/1728-8800-2022-3235. In Russian.

4. Yezhov M.V., Sergienko I.V., Kukharchuk V.V., et al. Lipid metabolism disorder. Clinical guidelines 2023. Russian Journal of Cardiology. 2023. 28(5). 5471. doi: 10.15829/1560-4071-2023-5471. In Russian.

5. Boytsov S.A., Shakhnovich R.M., Tereshchenko S.N. et al. Prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian Registry of Acute myocardial infarction REGION. Cardiology. 2022. 62(7). 12–22. doi: 10.18087/cardio.2022.7.n2051. In Russian.

6. Oganov R.G., Simanenkov V.I., Bakulin I.G., et al. Comorbid pathology in clinical practice. Algorithms for diagnosis and treatment. Cardiovascular therapy and prevention. 2019. 18(1). 5-66. doi: 10.15829/1728-8800-2019-1-5-66. In Russian.

7. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., et al. Comorbidity of patients with chronic non-communicable diseases in the practice of a general practitioner. The Eurasian leadership. Cardiovascular therapy and prevention. 2024. 23(3). 3996. doi: 10.15829/1728-8800-2024-3996. In Russian.

8. Boytsov S.A., Pogosova N.V., Ansheles A.A., et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023. 28(5). 5452. doi: 10.15829/1560-4071-2023-5452. In Russian.

9. Perone F., Bernardi M., Redheuil A., Mafrica D. Role of cardiovascular imaging in risk assessment: recent advances, gaps in evidence, and future directions. J Clin Med. 2023. 12(17). 5563. doi: 10.3390/jcm12175563.

10. Panattoni G., Desimone P., Toto F., et al. Cardiovascular risk assessment in daily clinical practice: when and how to use a risk score. Eur Heart J Suppl. 2025. 27(1). 16-21. doi: 10.1093/eurheartjsupp/suae100.

11. Kontsevaya A.V., Shal'nova S.A., Drapkina O.M. The study of the ESSAY-RF: epidemiology and public health promotion. Cardiovascular therapy and prevention.2021. 20(5). 2987. doi: 10.15829/1728-8800-2021-2987. In Russian.

12. Drapkina O.M., Shal'nova S.A., Imaeva A.E., et al. Epidemiology of cardiovascular diseases and their risk factors in the regions of the Russian Federation. The third study (ESSAY-RF-3). The rationale and design of the study. Cardiovascular therapy and prevention. 2022. 21(5). 3246. doi: 10.15829/1728-8800-2022-3246. In Russian.

13. Balanova Yu.A., Shal'nova S.A., Imaeva A.E., et al. Prediabetes: prevalence, associations with cardiovascular risk factors and contribution to survival in the Russian population. Cardiovascular therapy and prevention. 2024. 23(5). 4022. doi: 10.15829/1728-8800-2024-4022. In Russian.

14. Timmis A., Vardas P., Townsend N., et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022. 43(8). 716-799. doi: 10.1093/eurheartj/ehab892.

15. Barbarash O.L., Karpov Yu.A., Panov A.V., et al. Stable coronary artery disease. Clinical guidelines 2024. Russian Journal of Cardiology. 2024. 29(9). 6110. doi: 10.15829/1560-4071-2024-6110. In Russian.

16. Russian Society of Cardiology. Clinical recommendations. Acute myocardial infarction with ST segment elevation electrocardiograms. Russian Journal of Cardiology. 2025. 30(3). 6306. doi: 10.15829/1560-4071-2025-6306. In Russian.

17. Visseren F., Mach F., Smulders Y., Carballo D. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European Heart Journal. 2021. 42(34). 3227-3337. doi:10.1093/eurheartj/ehab484.

18. Kobalava J.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2024. Russian Journal of Cardiology. 2024. 29(9). 6117. doi: 10.15829/1560-4071-2024-6117. In Russian.

19. Mancia G., Kreutz R., Brunström M., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec. 41(12). 1874-2071. doi: 10.1097/HJH.0000000000003480.

20. Balanova Yu.A., Shal'nova S.A., Imaeva A. E. et al. Prevalence of arterial hypertension, coverage of treatment and its effectiveness in Of the Russian Federation (data from the ESSE-RF-2 observational study). Rational Pharmacotherapy in Cardiology. 2019. 15(4). 450-66. doi: 10.20996/1819-6446-2019-15-4-450-466. In Russian.

21. Tsao C.W., Aday A.W., Almarzooq Z.I., et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023. 147(8). 93-621. doi: 10.1161/CIR.0000000000001123.

22. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018. 36(10). 1953-2041. doi: 10.1097/HJH.0000000000001940.

23. Balanova Yu.A., Shal'nova S.A., Imaeva A.E., et al. Prevalence of arterial hypertension, coverage of treatment and its effectiveness in the Russian Federation (data from the ESSE-RF-2 observational study). Rational Pharmacotherapy in Cardiology. 2019. 15(4). 450-466. doi: 10.20996/1819-6446-2019-15-4-450-466. In Russian.

24. Kobalava J.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2024. Russian Journal of Cardiology. 2024. 29(9). 6117. doi: 10.15829/1560-4071-2024-6117. In Russian.

25. Averkov O.V., Barbarash O.L., Boytsov S.A., et al. Differentiated approach in diagnosis, formulation of diagnosis, management of patients and statistical accounting of type 2 myocardial infarction (agreed position). Russian Journal of Cardiology. 2019. (6). 7-21. doi: 10.15829/1560-4071-2019-6-7-21. In Russian.

26. Motova A.V., Karetnikova V.N., Barbarash O.L. Type 2 myocardial infarction: a modern view of the problem. Complex problems of cardiovascular diseases. 2023. 12(3). 192-199. doi: 10.17802/2306-1278-2023-12-3-192-199. In Russian.

27. Thygesen K., Alpert J.S., Jaffe A.S., et al. ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019. 40(3). 237-269. doi: 10.1161/CIR.0000000000000617.

28. Marx N., Federici M., Schütt K., et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023 Oct 14. 44(39). 4043-4140. doi: 10.1093/eurheartj/ehad192.

29. Temporelli P.L. Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes. Eur Heart J. 2025. 27(1). 1-5. doi: 10.1093/eurheartjsupp/suae086.

30. Kokozheva M.A., Mardanov B.Yu., Mamedov M.N. Acute coronary syndrome in diabetes mellitus: features of pathogenesis, course and therapy. Preventive medicine. 2021. 24(2). 89–96. doi: 10.17116/profmed20212402189. In Russian.

31. Dedov I.I., Shestakova M.V., Mayorova A.Yu., et al. Algorithms of specialized medical care for patients with diabetes mellitus. Diabetes mellitus. 2023. 26(2). 1-157. doi: 10.14341/DM13042. In Russian.

32. Mourtzinis G., Bager J-E., Andersson T. Does risk factor control beat familial predisposition for myocardial infarction? European Journal of Preventive Cardiology. 2025 Jan. 32(2). 139–140. doi: 10.1093/eurjpc/zwae188.

33. Shal'nova S.A., Drapkina O.M., Kutsenko V.A., et al. Myocardial infarction in the population of some regions of Russia and its prognostic significance. Russian Journal of Cardiology. 2022. 27(6). 4952. doi: 10.15829/1560-4071-2022-4952. In Russian.

34. Byrne R.A., Rossello X., Coughlan J.J, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Society of Cardiology (ESC). Eur. Heart J. Acute Cardiovasc. Care. 2024. 13. 55–161. doi: 10.1093/ehjacc/zuad107.

35. Mousavi I., Suffredini J., Virani S.S., et al. Early-onset atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology. 2025 Jan; 32(2). 100–112. doi: 10.1093/eurjpc/zwae240.

36. Møller A.L., Larson M.G., Xanthakis V., Vasan R.S., Andersson C. Modifiable risk factors and risk of myocardial infarction in offspring with parental disease. European Journal of Preventive Cardiology. 2025. 32(2). 131–138. doi: 10.1093/eurjpc/zwae169.

37. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004. 364(9438). 937-952. doi: 10.1016/S0140-6736(04)17018-9.

38. Belyalov F.I., Sumin A.N., Garganeeva N.P., et al. Mental disorders and cardiovascular diseases: clinical recommendations of the Baikal and Siberian Psychosomatic Associations. Complex problems of cardiovascular diseases. 2024. 13(3). 222-253. doi: 10.17802/2306-1278-2024-13-3S-222-253. In Russian.

39. Peskovets R.D., Shtarik S.Yu. Association of psychosocial risk factors and coronary heart disease in the open population of a large industrial center in Eastern Siberia. Siberian Medical Review. 2021. (5). 47-53. doi:10.20333/25000136-2021-5-47-53. In Russian.

40. Yezhov M.V., Kukharchuk V.V., Sergienko I.V., et al. Lipid metabolism disorders. Clinical guidelines 2023. Russian Journal of Cardiology. 2023 28(5). 5471. doi: 10.15829/1560-4071-2023-5471. In Russian.